Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic

BACKGROUND: Randomised trials of tamoxifen versus placebo indicate that tamoxifen reduces breast cancer risk by approximately 33%, yet uptake is low. Approximately 10% of women in our clinic entered the IBIS-I prevention trial. We assess the uptake of tamoxifen in a consecutive series of premenopaus...

Descripción completa

Detalles Bibliográficos
Autores principales: Donnelly, L S, Evans, D G, Wiseman, J, Fox, J, Greenhalgh, R, Affen, J, Juraskova, I, Stavrinos, P, Dawe, S, Cuzick, J, Howell, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3974072/
https://www.ncbi.nlm.nih.gov/pubmed/24594998
http://dx.doi.org/10.1038/bjc.2014.109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3974072/
https://www.ncbi.nlm.nih.gov/pubmed/24594998
http://dx.doi.org/10.1038/bjc.2014.109

Ejemplares similares